<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784743</url>
  </required_header>
  <id_info>
    <org_study_id>OMS/TDR ID# A00563</org_study_id>
    <nct_id>NCT02784743</nct_id>
  </id_info>
  <brief_title>Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali</brief_title>
  <official_title>Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Appui à la lutte contre la Maladie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaria Research and Training Center, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre d'Appui à la lutte contre la Maladie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lymphatic filariasis is a public health problem in Mali. The existing data are not up to date
      and most of them are more than 15 years old. To address this issue in April 2000, the
      investigators started studies to update the epidemiology of lymphatic filariasis. There is no
      ongoing lymphatic filariasis control program in 2000 in Mali in terms of preventive
      chemotherapy treatment or vector control.

      To fill these gaps, this current study aims to assess the impact of albendazole-ivermectin
      combination treatment on Wuchereria bancrofti infection and transmission in 6 rural highly
      endemic villages of Mali.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphatic filariasis is a public health problem in Mali. The existing data are not up to date
      and most of them are more than 15 years old. To address this issue in April 2000, the
      investigators started studies to update the epidemiology of lymphatic filariasis. As a
      result, in two rural areas (Banambani and Sirakoro) located at about 25 km North-East Bamako,
      the parasite prevalence using ICT cards in August 2000 were 16% (n=150) and 15.0% (n=113)
      respectively in Banambani and Sirakoro. There is no ongoing lymphatic filariasis control
      program in 2000 in Mali in terms of preventive chemotherapy treatment or vector control.

      To fill these gaps, this current study aims to assess the impact of albendazole-ivermectin
      combination treatment on Wuchereria bancrofti infection and transmission in 6 rural highly
      endemic villages of Mali.

      The study will be conducted in three phases: the pre treatment assessment of lymphatic
      filariasis infection and transmission parameters, treatment phase with annual single dose of
      albendazole and ivermectin and the post treatment assessment of Anopheles gambiae s.l
      mosquitoes, the transmission parameters of the vectors in the community, human infection
      prevalence post treatment using Giemsa -stained thick smears and others test like the Immuno
      chromatographic test (ICT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vector infection and infectivity rates</measure>
    <time_frame>up to 7 months</time_frame>
    <description>vectors are collected with human landing catch technique and the presence of Wb larvae stage s assessed using dissection method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post MDA adverses events related to the drug albendazo and ivermectin</measure>
    <time_frame>up to 12 months</time_frame>
    <description>after the administration of the drug the investigators assess the reaction to the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of albendazole ivermectin treatment on microfilaremia</measure>
    <time_frame>up to 12 months</time_frame>
    <description>night thick smears on eligible volunteers 5 years and above</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1139</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <arm_group>
    <arm_group_label>albendazole and ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before and after design with all eligible volunteers receiving the study drugs. Administration of a yearly unique dose of albendazole 400mg and ivermectin 150ug/kg weight ( according to the height).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>''albendazole'' and ''ivermectin''</intervention_name>
    <description>annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)</description>
    <arm_group_label>albendazole and ivermectin</arm_group_label>
    <other_name>Zentel and Mectizan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resident of the 6 villages

          -  5 years and above

        Exclusion Criteria:

          -  pregnant women

          -  breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sékou F Traoré, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malaria Research and Training Center, Mali</affiliation>
  </overall_official>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23981378</url>
    <description>Abstract of Baseline and first mass drug adminstration data</description>
  </link>
  <reference>
    <citation>Coulibaly YI, Dembele B, Diallo AA, Konaté S, Dolo H, Coulibaly SY, Doumbia SS, Soumaoro L, Coulibaly ME, Bockarie MJ, Molyneux D, Nutman TB, Klion AD, Toure YT, Traore SF. The Impact of Six Annual Rounds of Mass Drug Administration on Wuchereria bancrofti Infections in Humans and in Mosquitoes in Mali. Am J Trop Med Hyg. 2015 Aug;93(2):356-60. doi: 10.4269/ajtmh.14-0516. Epub 2015 Jun 1.</citation>
    <PMID>26033027</PMID>
  </reference>
  <results_reference>
    <citation>Coulibaly YI, Dembele B, Diallo AA, Kristensen S, Konate S, Dolo H, Dicko I, Sangare MB, Keita F, Boatin BA, Traore AK, Nutman TB, Klion AD, Touré YT, Traore SF. Wuchereria bancrofti transmission pattern in southern Mali prior to and following the institution of mass drug administration. Parasit Vectors. 2013 Aug 28;6(1):247. doi: 10.1186/1756-3305-6-247.</citation>
    <PMID>23981378</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>May 24, 2016</last_update_submitted>
  <last_update_submitted_qc>May 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wuchereria bancrofti</keyword>
  <keyword>Anopheles</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Ivermectin</keyword>
  <keyword>MDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

